Authentication analysis of animal fats adulteration in nail polish simulation using Raman spectroscopy coupled with chemometrics

Authors: Fadzillah, Nurrulhidayah Ahmad ^{a, ⁎}, Elgharbawy, Amal ^a, Jamaluddin, Mohammad Aizat ^a, Tukiran, Nur Azira ^a, Windarsih, Anjar ^b, Rohman, Abdul ^{c, d}, Sukri, Siti Jamilah Mohd ^e, Muhammad, Nurul Widad Fitri ^f, Hamid, Anis Hamizah ^g

Source: In Vibrational Spectroscopy May 2025 138

Precision medicine for prostate cancer: An international perspective

Authors: Hamid, Anis A., Sweeney, Christopher J., Hovens, Christopher, Corcoran, Niall, Azad, Arun A.

Source: In Urologic Oncology: Seminars and Original Investigations December 2024 42(12):392-401

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Authors: Akhurst, Tim, Alipour, Ramin, Bailey, Dale, Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Crumbaker, Megan, Dhiantravan, Nattakorn, Hamid, Anis, Haskali, Mohammad, Hung, Terry, Kong, Grace, Lawrence, Nick, Lewin, Jeremy, McCarthy, Michael, Moodie, Kate, Murphy, Declan, Nguyen, Andrew, Pook, David, Ravi Kumar, Aravind, Roach, Paul, Roselt, Peter, Saghebi, Javad, Schembri, Geoff, Spain, Lavinia, Subramaniam, Shalini, Thang, Sue Ping, Thomas, Paul, Tran, Ben, Wallace, Roslyn, Yip, Sonia, Hofman, Michael S ^*, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R, Williams, Scott G, Martin, Andrew J, Davis, Ian D

Source: In The Lancet Oncology January 2024 25(1):99-107

A novel prostate cancer subtyping classifier based on luminal and basal phenotypes

Authors: Weiner, Adam B., Liu, Yang, Hakansson, Alex, Zhao, Xin, Proudfoot, James A., Ho, Julian, Zhang, JJ H., Li, Eric V., Karnes, R. Jeffrey, Den, Robert B., Kishan, Amar U., Reiter, Robert E., Hamid, Anis A., Ross, Ashely E., Tran, Phuoc T., Davicioni, Elai, Spratt, Daniel E., Attard, Gerhardt, Lotan, Tamara L., Lee Kiang Chua, Melvin, Sweeney, Christopher J., Schaeffer, Edward M.

Source: Cancer. 129(14):2169-2178

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185725893.0x000001&indx=1&recIds=ETOCvdc_100185725893.0x000001

Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer

Authors: Degeling, Koen, Corcoran, Niall M., Pereira-Salgado, Amanda, Hamid, Anis A., Siva, Shankar, IJzerman, Maarten J.

Source: In Value in Health December 2021 24(12):1737-1745

A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy

Authors: Fankhauser, Christian Daniel, Tran, Ben, Pedregal, Manuel, Ruiz-Morales, José Manuel, Gonzalez-Billalabeitia, Egon, Patrikidou, Anna, Amir, Eitan, Seidel, Christoph, Bokemeyer, Carsten, Hermanns, Thomas, Rumyantsev, Alexey, Tryakin, Alexey, Brito, Margarida, Fléchon, Aude, Kwan, Edmon M., Cheng, Tina, Castellano, Daniel, del Muro, Xavier Garcia, Hamid, Anis A., Ottaviano, Margaret, Palmieri, Giovanella, Kitson, Robert, Reid, Alison, Heng, Daniel Y.C., Bedard, Philippe L., Sweeney, Christopher J., Connors, Jean M.

Source: In European Urology Focus September 2021 7(5):1130-1136

A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer

Authors: Wang, Victoria, Geybels, Milan S., Jordahl, Kristina M., Gerke, Travis, Hamid, Anis, Penney, Kathryn L., Markt, Sarah C., Freedman, Matthew, Pomerantz, Mark, Lee, Gwo‐Shu M., Rana, Huma, Börnigen, Daniela, Rebbeck, Timothy R., Huttenhower, Curtis, Eeles, Ros A., Stanford, Janet L., Consortium, Practical, Berndt, Sonja I., Claessens, Frank, Sørensen, Karina D., Park, Jong Y., Vega, Ana, Usmani, Nawaid, Mucci, Lorelei, Sweeney, Christopher J.

Source: Prostate. 81(10):683-693

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100121742398.0x000001&indx=1&recIds=ETOCvdc_100121742398.0x000001

Association between CD8 and PD‐L1 expression and outcomes after radical prostatectomy for localized prostate cancer

Authors: Vicier, Cecile, Ravi, Praful, Kwak, Lucia, Werner, Lillian, Huang, Ying, Evan, Carolyn, Loda, Massimo, Hamid, Anis A., Sweeney, Christopher J.

Source: Prostate. 81(1):50-57

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100111478042.0x000001&indx=1&recIds=ETOCvdc_100111478042.0x000001

Nursing Implications of Recent Changes in Management Practices for Metastatic Prostate Cancer

Authors: Bennett, Caitlin, Davis, Ian D., Hamid, Anis A.

Source: In Seminars in Oncology Nursing August 2020 36(4)

Testicular seminoma metastases presenting as gastrointestinal malignancy: A case report and review of the literature

Authors: Thomson, Alice, Keong, Ben, Longano, Anthony, Hamid, Anis, Sengupta, Shomik

Source: ANZ journal of surgery. 92(1-2):271-273

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100143435290.0x000001&indx=1&recIds=ETOCvdc_100143435290.0x000001

Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy

Authors: Hamid, Anis A., Gray, Kathryn P., Huang, Ying, Bowden, Michaela, Pomerantz, Mark, Loda, Massimo, Sweeney, Christopher J.

Source: In European Urology Oncology September 2019 2(5):475-482

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer

Authors: Hamid, Anis A., Gray, Kathryn P., Shaw, Grace, MacConaill, Laura E., Evan, Carolyn, Bernard, Brandon, Loda, Massimo, Corcoran, Niall M., Van Allen, Eliezer M., Choudhury, Atish D., Sweeney, Christopher J.

Source: In European Urology July 2019 76(1):89-97

Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)

Authors: Tran, Ben, Ruiz‐Morales, Jose M., Gonzalez‐Billalabeitia, Enrique, Patrikidou, Anna, Amir, Eitan, Seidel, Christoph, Bokemeyer, Carsten, Fankhauser, Christian, Hermanns, Thomas, Rumyantsev, Alexey, Tryakin, Alexey, Brito, Margarida, Fléchon, Aude, Kwan, Edmond Michael, Cheng, Tina, Castellano, Daniel, Garcia del Muro, Xavier, Hamid, Anis A., Ottaviano, Margaret, Palmieri, Giovannella, Kitson, Robert, Reid, Alison, Heng, Daniel Y. C., Bedard, Philippe L.

Source: Cancer medicine. 9(1):116-124

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100097861359.0x000001&indx=1&recIds=ETOCvdc_100097861359.0x000001

Impact of baseline serum IL‐8 on metastatic hormone‐sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805)

Authors: Harshman, Lauren C., Wang, Victoria X., Hamid, Anis A., Santone, Gabriella, Drake, Charles G., Carducci, Michael A., DiPaola, Robert S., Fichorova, Raina N., Sweeney, Christopher J.

Source: Prostate. 80(16):1429-1437

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100109071811.0x000001&indx=1&recIds=ETOCvdc_100109071811.0x000001

Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era

Authors: Hamid, Anis A., Markt, Sarah C., Vicier, Cécile, McDermott, Kathleen, Richardson, Paul, Ho, Vincent T., Sweeney, Christopher J.

Source: In Clinical Genitourinary Cancer February 2019 17(1):58-64

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry

Authors: Francini, Edoardo, Gray, Kathryn, Shaw, Grace, Evan, Carolyn, Hamid, Anis, Perry, Caitlin, Kantoff, Philip, Taplin, Mary-Ellen, Sweeney, Christopher

Source: Prostate cancer and prostatic diseases. 22(3):420-427

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100189398157.0x000001&indx=1&recIds=ETOCvdc_100189398157.0x000001

Association of DAZL expression with risk of recurrence in clinical stage 1 testicular germ cell tumors.

Authors: Tewari, Alok, Hamid, Anis, Huang, Jiaming, Zhong, Caiwei, Xie, Wanling, Rothmann, Emily, Nicholls, Peter, Walk, Nathan, Brcic, Iva, Terbuch, Angelika, Van Allen, Eliezer Mendel, Sweeney, Christopher

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p523-523, 25p

A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors.

Authors: Richardson, Gary Edward, Al-Rajabi, Raed, Uprety, Dipesh, Hamid, Anis, Williamson, Stephen K., Baranda, Joaquina, Mamdani, Hirva, Lee, Ya-Li, Nitika, Li, Li, Wang, Xingli, Dong, Xunwei

Source: Cancers; May2023, Vol. 15 Issue 9, p2553, 10p

Subject Terms: RESEARCH, DRUG efficacy, DRUG dosage, GENETIC mutation, PROTEIN-tyrosine kinase inhibitors, TREATMENT effectiveness, DESCRIPTIVE statistics, RESEARCH funding, TUMORS, DRUG side effects, PATIENT safety, DRUG toxicity, PHARMACODYNAMICS

Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature.

Authors: John, Alexius, Spain, Lavinia, Hamid, Anis A.

Source: Current Oncology; Jan2023, Vol. 30 Issue 1, p923-937, 15p, 6 Charts

Subject Terms: RENAL cell carcinoma, IMMUNOTHERAPY, CLINICAL trials, THERAPEUTICS, MEDICAL care, MEDICAL personnel

Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose‐reduced 3‐weekly docetaxel for metastatic castration‐resistant prostate cancer.

Authors: Hamid, Anis A.¹, Willson, Kaspar¹, Tamjid, Babak¹, Campbell, Ainsley¹, Stewart, Josephine¹, Weickhardt, Andrew J.¹, Vincent, Andrew D.², Lee, Margaret³, Pezaro, Carmel³, Bergin, Alice⁴, Tran, Ben^4,5,6, Gan, Chun⁵

Source: Asia Pacific Journal of Clinical Oncology. Oct2018, Vol. 14 Issue 5, pe399-e404. 6p.

Subject Terms: *DOCETAXEL, *CASTRATION-resistant prostate cancer, *FEBRILE neutropenia, *CANCER chemotherapy, *PROSTATE-specific antigen, *DOSAGE forms of drugs, *CANCER treatment, *DISEASE risk factors